 BURLINGAME, Calif.--BUSINESS WIRE--Humanigen, Inc., HGEN Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumabTM, today announced that the company and the Department of Defense DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense JPEO-CBRND or JPEO have entered into a Cooperative Research and Development Agreement CRADA 